Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)

Not Applicable

Active, not recruiting

• Conditions: Cancer, Breast; Cardiotoxicity; Cardiovascular Diseases

• Registration Number: NCT03748550
• Lead Sponsor: Nova Scotia Health Authority

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-13
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - <br><br> 1) must be 18 years or older.<br><br> - diagnosed with breast cancer (stages I-III) and not have started therapy.<br><br> - must be scheduled to receive AC- based chemotherapy (minimum dose of 240 mg/m2 of<br> DOX or 300 mg/m2 of DAN).<br><br> - are able to undertake a 12-week home-based, progressive aerobic exercise program.<br><br> - have medical clearance from a cardiologist (e.g. based on stress test results) to<br> participate in the study.<br><br>Exclusion Criteria:<br><br> - significant cognitive limitations.<br><br> - pre-existing medical condition that would otherwise contraindicate aerobic exercise.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Left Ventricular (LV) Function

Secondary Outcome Measures

Name	Time	Method
Change in Cardiac Electrical Activity;Change in Aerobic Fitness;Change in Blood biomarkers;Change in Functional Assessment for Cancer Therapy;Change in Fatigue